Johan Richter

9PUBLICATIONS
54CO-AUTHORS
Molecular targetsHaematological tumoursEpidemiological modellingCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jun 18, 2026
Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study.

|Jul 11, 2025
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.

Jane F Apperley, Dragana Milojkovic, Nicholas C P Cross

|Jul 10, 2024
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial.

Fabio Efficace, Francois-Xavier Mahon, Johan Richter

|Jan 26, 2024
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.

Hjalmar Flygt, Stina Söderlund, Johan Richter

|Dec 21, 2023
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib.

Katerina Machova Polakova, Ali Albeer, Vaclava Polivkova

|Jan 11, 2022
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study.

Torsten Dahlén, Gustaf Edgren, Per Ljungman

Pageof 2

Frequent Collaborators

8 joint publications

Susanne Saussele

4 joint publications

Henrik Hjorth-Hansen

4 joint publications

Markus Pfirrmann

3 joint publications

Hjalmar Flygt